Document is current

Article History

Received: 13 February 2023

Accepted: 25 April 2023

First Online: 29 May 2023

Declarations

:

: C. Kratochwil is a coinventor of PSMA-617 and worked as a scientific consultant for AAA/Novartis, Roche, AdvanCell, Telix. R.J. Hicks is a shareholder of Telix Pharmaceuticals and Founder and Director of PreMIT Pty Ltd. W.J.G. Oyen received speaker fees from Astellas and did advisory boards for AAA/Novartis and Debiopharm. M. Hofman acknowledged philanthropic/government grant support from the Prostate Cancer Foundation (PCF) funded by CANICA Oslo Norway, Peter MacCallum Foundation, Medical Research Future Fund, NHMRC Investigator Grant, Movember, U.S. Department of Defense and the Prostate Cancer Foundation of Australia (PCFA); he received grant support from AAA/Novartis, ANSTO, Bayer, Isotopia, and consulting fees for lectures or advisory boards from Astellas, AstraZeneca, Janssen, Merck/MSD, Mundipharma, and Point Biopharma. K. Kopka is a coinventor of PSMA-617, PSMA-914, and PSMA-1007 and a member of the Scientific Advisory Board of Telix Pharmaceuticals. U. Haberkorn is a coinventor of PSMA-617. W. P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speakers bureau), Calyx (consultant), Bayer (consultant, speakers bureau, research funding), Parexel (image review), Novartis (speakers bureau), and Telix (speakers bureau). M. Eiber reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. K. Hermann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from Boston Scientific, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Pharma15, personal fees from Theragnostics Ltd., personal fees from Janssen, personal fees from Telix, personal fees from Debiopharm, personal fees from Bain Capital, and personal fees from Eco1R all outside the submitted work. The other authors declared no personal conflict of interest in the field.